Similar companies
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Revenue | 31M | 3735.5% |
Gross Profit | -260,000 | 95.9% |
Cost of Revenue | 31M | 332% |
Operating expense | 107M | 7.5% |
Net Income | -97M | 14.1% |
EBITDA | -96M | 14.7% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 964M | 10.9% |
Total Liabilities | 196M | 3.1% |
Total Equity | 769M | 13% |
Shares Outstanding | 297M | 6.3% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | -98M | 19.5% |
Cash from investing | 40M | 136.1% |
Cash from financing | 153M | 21.1% |
EPS
Financial Highlights for Iovance Biotherapeutics in Q2 '24
Iovance Biotherapeutics reported a revenue of 31M, which is a 3735.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -260,000, marking a 95.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 31M, a 332% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 107M, showing a -7.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -97M, showing a 14.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -96M, showing a 14.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Iovance Biotherapeutics with growth in revenue, gross profit, and net income.